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Rosiglitazone increases endothelial cell
migration and vascular permeability
through Akt phosphorylation
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Abstract
Background: Thiazolidinediones (TZDs), peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists, exhibit
anti-inflammatory and antioxidant properties and inhibit endothelial inflammation and dysfunction, which is
anti-atherogenic. However, fluid retention, which may lead to congestive heart failure and peripheral edema,
is also a concern, which may result from endothelial cell leakage. In the current study, we examined the
effects of PPAR-γ agonists on vascular endothelial cell migration and permeability in order to determine its
underlying mechanisms.
Methods: We used rosiglitazone and conducted cell migration assay and permeability assay using HUVEC
cells and measured vascular permeability and leakage in male C57BL/6 mice.
Results: Rosiglitazone significantly promoted endothelial cell migration and induced permeability via activation of
phosphatidylinositol-3-kinase (PI3K) – Akt or protein kinase C (PKC)β. In addition, rosiglitazone increased
vascular endothelial growth factor (VEGF) expression and suppressed expression of tight junction proteins
(JAM-A and ZO-1), which might promote neovascularization and vascular leakage. These phenomena were
reduced by Akt inhibition.
Conclusions: Vascular endothelial cell migration and permeability change through Akt phosphorylation might
be a mechanism of induced fluid retention and peripheral tissue edema by TZD.
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Background
Cardiovascular disease is a leading cause of death related
to atherosclerosis. Atherosclerosis arises from a series of
proinflammatory, proliferative, and procoagulatory
processes [1, 2]. Compromised endothelial cell function
plays a critical role in the development of atherosclerosis
[3]. Endothelial dysfunction can be characterized as an
alteration in cell migration and permeability. Endothelial
cell migration involves the neovascularization of athero-
sclerotic plaques and causes plaques to become vulner-
able. In addition, newly formed small vessels can provide
an entry for inflammatory cells [4]. Under physiological
conditions, endothelial cells provide a barrier between
blood vessels and tissues [5, 6]. However, inflammatory
stimuli can increase endothelial permeability [6, 7] and
enable the movement of macromolecules such as vascular
endothelial growth factor (VEGF), which can induce
neovascularization [8, 9]. It is suggested that endothelial
cell migration is induced by angiogenic factors such as
VEGF and linked to the phosphatidylinositol-3-kinase
(PI3K) – Akt pathway for neovascularization [10–12].
Endothelial cells must adhere to extracellular matrix for
their survival [9, 13] and cellular adhesion to matrix is
mediated by a few junctional proteins. During the process
of atherosclerosis, tight junctions of endothelial cells
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Peroxisome proliferator-activated receptors (PPARs)
are nuclear receptor families that have critical functions
in lipid homeostasis and peripheral insulin sensitivity
[15]. PPAR-γ is essential for adipocyte differentiation
[16] and fat storage [17, 18]. It is also the molecular tar-
get of the thiazolidinedione (TZD) class of anti-diabetic
drugs such as rosiglitazone [19]. PPAR-γ is expressed in
endothelial cells [20] and previous preclinical studies
have reported that PPAR-γ agonist inhibit endothelial in-
flammation and dysfunction [21]. In clinical practice,
fluid retention such as peripheral edema and congestive
heart failure is known as the most common and serious
side effect of TZDs and has become the most frequent
cause of discontinuation of therapy [22]. Conflicting data
have been reported with regard to the mechanism by
which TZD acts on vascular endothelial cells.
In endothelial cells, cellular signaling is dependent on
two major pathways – PI3K/Akt/mTOR pathway and
ERK/MAPK (extracellular signal-regulated kinases/mito-
gen-activated protein kinases) pathway. TZDs were re-
ported to affect vascular constriction by inhibiting PI3K/
Akt pathway [23] and the stimulation of PPAR-γ by
TZDs activates the MEPK / ERK pathway and promotes
adipogenesis [24]. In addition, the overexpression of
PKCβ in endothelial cells has been reported to inhibit
Akt phosphorylation and affect PI3K/Akt pathway [25].
In the current study, we hypothesized that one of the
thiazolidinediones, rosiglitazone acts positively in terms
of smooth muscle cell migration, endothelial cell repair,
and vascular inflammation, but negatively affects blood
vessel leakage, leading to leakage and increased edema
and examined the effect of rosiglitazone on the expres-
sion of VEGF and PI3K-Akt signaling in human umbil-
ical vascular endothelial cells (HUVEC) and mice fed a
high fat diet (HFD).
Methods
Drugs
Rosiglitazone, PI3K inhibitor (LY294002), Akt specific
inhibitor, and protein kinase C (PKC) β inhibitor were
purchased from Calbiochem (San Diego, CA, USA).
Cell culture
Primary HUVECs (CC-2519, Cambrex, Walkersville,
MD, USA) were cultured in endothelial cell growth
medium (EGM)-2 (Cambrex) containing 2% fetal bovine
serum (FBS), 0.4% hydrocortisone, 4% hFGF-B, 0.1%
VEGF, 0.1% R3-IGF, 0.1% ascorbic acid, 0.1% hEGF, 0.1%
GA-1000, and 0.1% heparin. Cells were grown at 37 °C
and 5% CO2. For the experiment, HUVECs were starved
in endothelial cell basal medium (EBM)-2 (Cambrex)
supplemented with 0.4% FBS for 24 h. HUVECs of
passages 2–9 were used in the experiments.
Wound healing assay
HUVECs were grown to confluence in 6-well plates
(NalgeNunc, Rochester, NY, USA). Each well was
scratched with a 1000 μL pipette tip to generate wounds
and then starved as described above with or without rosi-
glitazone. At least 3 images were taken using a microscope
and the distance moved was measured to estimate cell
migration.
Transwell migration assay
The modified Boyden chamber assay was performed using
a Transwell system (Corning, Rochester, NY, USA). The
insert had a polycarbonate membrane with 8 μm pores
which enable migration of cells. Each insert was coated
with a 10 μg gelatin solution and 104 HUVEC cells in
starvation medium were loaded onto the insert. Each well
was filled with 500 μL of starvation medium with or
without rosiglitazone and inserts were placed in 24-well
plates. After 24 h, the upper surface of the inserts was
swabbed with a cotton-tipped applicator for removal of
non-migrating cells. Inserts were fixed in methanol for
10 min and stained with 1% crystal violet for 2 h. The
number of cells that had moved was counted to estimate
cell migration.
Transwell monolayer permeability assay
HUVECs (8 × 105/well) were seeded on 2 μm PET
Transwell inserts (Falcon, USA) and grown to conflu-
ence with EGM-2. The confluence, integrity, and
uniformity of the endothelial cell monolayer were exam-
ined microscopically. Before performing the experiment,
cells were starved for 24 h with rosiglitazone and inhibi-
tors. To determine the permeability through the cell
monolayer, Evans Blue (EB) bound to 0.1% bovine serum
albumin (BSA) in phosphate-buffered saline (PBS) was
loaded onto the upper chamber. EB could leak through
intercellular spaces without junction or endothelial cell
fenestration into the lower chamber. After 1 h, the
amount of EB in the lower chamber was determined by
spectrophotometer (620 nm). Experiments were
performed in triplicate and repeated multiple times.
Immunofluorescence staining
Cells were plated into 8-well slide chambers (Sonic Seal
Slides, NalgeNunc). Cells were grown with EBM-2 and
reagents for 24 h, respectively. Then, cells were fixed in
absolute methanol and washed with PBS containing
0.4% Tween-20. After washing, cells were blocked with
PBS containing 10% goat serum, followed by incubation
with rabbit polyclonal anti-phospo-Akt (ser473), anti-
VEGF, anti-junction adhesion molecule-A (JAM-A),
anti-ZO-1, and anti-VEGF antibodies overnight. Cells
were processed using FITC-conjugated bovine anti-
rabbit antibody. DAPI (1 μg/mL) was used for nuclei
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counter staining. Images were acquired on a Zeiss or
Leitzorthoplan microscope (Leica Inc., Wetzlar,
Germany) or a Leica DMIRBE inverted epifluorescence
Nomarski microscope with Leica TCS NT confocal laser
optics.
Western blot
Cells were harvested and solubilized in cell lysis buffer (Cell
Signaling, Beverly, MA, USA) for 30 min at 4 °C. Protein
concentration was measured using a Bradford protein assay
kit (BioRad, Hercules, CA, USA). The same amounts of
proteins from whole cell lysates were subjected to SDS
polyacrylamide gel electrophoresis and transferred onto
methanol-treated PVDF membranes (Millipore Co,
Bedford, MA, USA). The membrane was immunoblotted
with antibodies against phospho-Akt, VEGF, JAM-A (Santa
Cruz, CA, USA), phospho-PKCβ, ZO-1 (Abcam,
Cambridge, MA, USA), and β-actin (Sigma-Aldrich, St.
Louis, MO, USA), respectively, overnight at 4 °C. The
membranes were washed and incubated for 1 h at room
temperature with HRP-conjugated secondary antibodies.
After extensive washing, the bands were detected using an
enhanced chemiluminescence (ECL) kit (Santa Cruz).
siRNA transfection
Endogenous Akt activity was inhibited using an RNA
interference technique. HUVECs were grown to 80%
confluence in a 6-well plate and 40 nM of nonspecific or
Akt-1 specific small interfering RNA (siRNA) (Santa
Cruz) were transfected into HUVECs according to the
manufacturer’s instructions with Lipofectamine 2000
reagent (Invitrogen).
Animals
Male C57BL/6 mice obtained from the central labora-
tory animal facility (Seoul, Korea) were grown to 6 weeks
of age and fed a high fat diet (HFD). At 8 weeks of age,
Ed – the C57BL/6 mice were divided into 4 groups;
control group (intraperitoneal injection with normal sa-
line; n = 6), rosiglitazone group (5 mg/kg/day rosiglita-
zone [26–29] in diet and injection with normal saline;
n = 6), Akt inhibitor group (intraperitoneal injection 2
times a week with 0.15 mg/kg [30, 31] of Akt inhibitor
with normal saline; n = 6), rosiglitazone with Akt inhibi-
tor group (5 mg/kg/day rosiglitazone in diet and injec-
tion 2 times a week with 0.15 mg/kg of Akt inhibitor
with normal saline; n = 6) for 8 weeks. The body weight
was approximately 35 g in the control group and tended
to increase by rosiglitazone, but this was not statistically
significant (Fig. 1a). Fasting glucose level was 190–
200 mg/dL in control group, whereas 175–180 mg/dL in
rosiglitazone group (Fig. 1b). Akt inhibitor did not make
a difference in body weight and blood glucose, compared
to control (Fig. 1b). Mice were anesthetized intraperito-
neally with a combination of ketamine (70 mg/kg) and
xylazine (7 mg/kg; Yuhan Corp, Bayer Korea). All
animals were handled in compliance with the Guide for
Experimental Animal Research of the Laboratory of
Clinical Research Institute, Seoul National University
Bundang Hospital. No irritability or restlessness was
observed after administration of drug or vehicle. No
noticeable adverse effects (e.g., respiratory distress,
abnormal locomotion, or catalepsy) were observed in
any animals. All mice were maintained in plastic cages
in an air-conditioned room at 22 ± 2 °C and 55 ± 10%
humidity.
Fig. 1 Effects of rosiglitazone or AKT inhibitor on body weight and blood glucose level. a Body weight in control, rosiglitazone, Akt inhibitor and
rosiglitazone + Akt inhibitor groups. There was a tendency for body weight to increase with rosiglitazone treatment, but there was no statistically
significant difference between the four groups (P = NS). b Blood glucose levels in four groups. There was a statistically significant decrease in
blood glucose in the rosiglitazone group (*P < 0.05)
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Measurement of vascular permeability with Evans
blue dye
EB dye does not bind covalently to plasma albumin, a
marker for proteins around 67 Ed –kDa. Under deep
anesthesia, EB dye was injected into a limb artery of male
C57BL/6 mice. After 30 min, perfusion with normal saline
was administered for 2 min in each mouse to clear the dye
from the left ventricle. The main arteries were removed
immediately and then frozen in OCT compound.
Remaining tissues were flash frozen with liquid N2 and
kept at −80 °C. The eyes were marked for orientation,
enucleated, and placed in 4% paraformaldehyde for 3 to
24 h. Lenses were removed and peripheral retinas were
cut up to allow flat mounting with glycerol-gelatin. Images
were acquired on a Zeiss or Leitzorthoplan microscope
(Leica Inc., Wetzlar, Germany) or a Leica DMIRBE
inverted epifluorescence Nomarski microscope with Leica
TCS NT confocal laser optics.
Statistical analysis
Results are reported as the mean ± SEM. Mean
values were compared between the drug treatment
and control groups by analysis of variance (ANOVA)
with a post hoc test, and P < 0.01 was considered
statistically significant.
Results
Rosiglitazone promoted the migration of HUVECs
HUVECs were treated with rosiglitazone (1, 5 or
10 μM) for 24 h. In a wound healing assay, 5 and
10 μM of rosiglitazone increased cell migration com-
pared with control (237 ± 17% and 284 ± 22%, re-
spectively; Fig. 2a and b). In a Transwell migration
assay, 5 and 10 μM of rosiglitazone also increased cell
migration (169 ± 11% and 195 ± 15%, respectively;
Fig. 2c and d) in a dose-dependent manner.
Fig. 2 Rosiglitazone promoted the migration of HUVECs. a and b Cell migration was assessed by a wound healing assay. Representative
micrographs at × 400 magnification (a) and the distance moved of cells (b) without or with rosiglitazone (1, 5, or 10 μM) for 24 h are shown. c
and d Cell migration was assessed by a Transwell migration assay. Representative micrographs at × 400 magnification (c) and the number of cells
that moved without or with rosiglitazone (1, 5, or 10 μM) for 24 h are shown. Data are represented as % of control. (n = 4; * p < 0.01 compared
with control)
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PI3K, Akt, or PKCβ inhibitor suppressed the rosiglitazone-
induced endothelial cell migration and permeability
We examined the effect of PI3K, Akt, or PKCβ inhibitor
on rosiglitazone-induced cell migration. HUVECs were
treated with rosiglitazone (10 μM) and inhibitors for
24 h. None of the inhibitors affected cell migration with-
out rosiglitazone. However, rosiglitazone induced signifi-
cantly increased cell migration and all inhibitors
suppressed rosiglitazone-induced cell migration (Fig. 3a).
LY294002 (PI3K inhibitor), Akt inhibitor, and PKCβ in-
hibitor decreased rosiglitazone-induced cell migration by
56, 59, and 57%, respectively (Fig. 3b).
We also tested the effect of rosiglitazone on endothelial
cell permeability. HUVECs were treated with rosiglitazone
(10 μM) and inhibitors for 24 h. In a Transwell monolayer
permeability assay, none of the inhibitors affected cell
permeability without rosiglitazone, however, rosiglitazone
increased cell permeability by 191 ± 54% compared with
control and all inhibitors which blocked rosiglitazone-
induced cell permeability. The leakage of EB was
decreased by 50, 53, and 61%, respectively (Fig. 3c).
These results suggest that rosiglitazone induced an
increase in migration and permeability of HUVECs
through activation of PI3K/Akt or PKCβ.
Rosiglitazone activated PI3K, Akt, and PKCβ
We found that rosiglitazone-induced endothelial cell mi-
gration and permeability was related to PI3K, Akt, and
PKCβ activity. To confirm the role of rosiglitazone on Akt
activity, we examined the phosphorylation of Akt in
rosiglitazone-treated HUVECs. Immunofluorescence
staining was performed with anti-phospho-Akt antibody.
Rosiglitazone increased the phosphorylation of Akt, which
is substantially abundant in the nucleus. However,
treatment with LY294002, Akt inhibitor, or PKCβ inhibi-
tor with rosiglitazone resulted in reduced phosphorylation
of Akt (Fig. 4a). Western blot analysis also showed that
rosiglitazone dramatically increased the phosphorylation
of PKCβ and Akt. LY294002 and PKCβ inhibitor remark-
ably reduced the phosphorylation of Akt and PKCβ, but
Akt inhibitor did not affect the phosphorylation of PKCβ
(Fig. 4b and c).
Rosiglitazone increased VEGF expression
VEGF is a potent growth factor for angiogenesis. As
shown in Fig. 5a, rosiglitazone significantly increased
VEGF expression compared with controls and it was
suppressed by LY294002, Akt Inhibitor, and PKCβ in-
hibitor. Western blot analysis also showed that rosiglita-
zone markedly increased VEGF and LY294002, Akt
Inhibitor or PKCβ inhibitor decreased rosiglitazone-
induced VEGF expression (Fig. 5b and c).
Rosiglitazone suppressed the expression of tight junction
proteins
Intercellular tight junctions are an important struc-
ture in endothelial cells. To understand the effect of
rosiglitazone on intercellular junctions, we examined
the expression and distribution of two junction pro-
teins, JAM-A and ZO-1 in HUVEC monolayer using
immunofluorescence staining (Fig. 6a and b). In un-
stimulated cells, JAM-A and ZO-1 were highly
expressed on the cell surface and concentrated at
cell-cell junctions. Treatment with rosiglitazone re-
sulted in decreased expression of JAM-A and ZO-1
and LY294002, Akt inhibitor, or PKCβ inhibitor
Fig. 3 PI3K, Akt, or PKCβ inhibitor suppressed the rosiglitazone-induced
endothelial cell migration and permeability. a HUVECs were treated with
rosiglitazone (10 μM) with or without PI3K inhibitors LY294002 (1 μM),
Akt inhibitor (3.5 μM), or PKCβ inhibitor (1.5 μM) simultaneously.
Representative micrographs at × 400 magnification. b The numbers of
cells that moved were counted. Data are represented as % of control. c
HUVECs were treated with rosiglitazone (10 μM) with or without PI3K
inhibitors LY294002 (1 μM), Akt inhibitor (3.5 μM), or PKCβ inhibitor
(1.5 μM) simultaneously. The leakage of EB bounded to albumin from
the upper to lower chamber was measured. Data are represented as %
of control. (n = 4; * p < 0.01 compared with control, † p < 0.01
compared with wells treated with rosiglitazone only)
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recovered the expression. The results of western blot ana-
lysis were in accordance with these results (Fig. 6c and d).
siRNA against Akt-1 inhibits rosiglitazone-induced cell
migration
To examine the effect of Akt signaling on
rosiglitazone-induced cell migration, endogenous Akt
was suppressed using siRNA. HUVECs transfected
with Akt-1 specific siRNA or with non-targeting
siRNA were compared. Transfected cells were treated
with rosiglitazone and cell migration was assessed
using a wound healing assay (Fig. 7a). Akt siRNA
inhibited rosiglitazone induced cell migration by
47 ± 7% compared with control (Fig. 7b). In western
blot analysis, the transfection of Akt-1 siRNA effectively
reduced endogenous expression of Akt (Fig. 7c and d) and
decreased VEGF expression, which was increased by treat-
ment with rosiglitazone and the expression of JAM-A and
ZO-1 was also reversed. However, there was no remark-
able change in the phosphorylation of PKCβ.
Rosiglitazone increased neovascularization and vascular
leakage in retina and aorta
We found that rosiglitazone increased VEGF expression in
vitro. We then performed EB staining to examine the effect
of rosiglitazone on neovascularization in retina of mice. Ad-
ministration of rosiglitazone in HFD-fed mice resulted in
significantly increased neovascularization (Fig. 8a) and vas-
cular leakage (Fig. 8b) in retina. To clarify the role of Akt in
rosiglitazone-mediated retinal neovascularization, Akt in-
hibitor was injected intraperitoneally. Development of ret-
inal neovascularization by rosiglitazone was effectively
suppressed by Akt inhibitor (Fig. 8c). In aorta of mice,
Fig. 4 Rosiglitazone activated the phosphorylation of Akt and PKCβ. a
HUVECs were treated with rosiglitazone (10 μM) with or without PI3K
inhibitors LY294002 (1 μM), Akt inhibitor (3.5 μM), or PKCβ inhibitor (1.5
μM) simultaneously. Cells were stained with anti-phospho-Akt
antibody. b and c Immunoblot analysis for the phosphorylation of Akt
and PKCβ (n = 4)
Fig. 5 Rosiglitazone increased VEGF expression. a HUVECs were
treated with rosiglitazone (10 μM) with or without PI3K inhibitors
LY294002 (1 μM), Akt inhibitor (3.5 μM), or PKCβ inhibitor (1.5 μM)
simultaneously. Cells were stained with anti-VEGF antibody. b and c
Immunoblot analysis for the expression of VEGF (n = 4)
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rosiglitazone also increased vascular leakage, however injec-
tion of Akt inhibitor with rosiglitazone inhibited vascular
leakage (Fig. 8d and e).
Discussion
Atherosclerosis is the primary cause of mortality in
patients with type 2 diabetes [32]. Vascular smooth
muscle cell (VSMC) proliferation contributes signifi-
cantly to intimal thickening in atherosclerosis, leading
to development of cardiovascular diseases [32]. PPAR-
γ agonists such as rosiglitazone have been suggested
to inhibit growth and migration of VSMC, with
potential favorable effects on atherosclerosis [33].
Peripheral edema formation is a well-known side ef-
fect of rosiglitazone. The precise mechanism of this
adverse effect is unclear [22], but may involve a
number of factors, notably VEGF, nitric oxide, and
protein kinase C, etc. [34]. We focused on vascular
endothelial cells, not VSMC and supposed that the
change of vascular endothelial cell migration and
permeability was an important factor which attributed
to peripheral edema formation of TZD.
Vascular endothelial cells are activated by physiological
agonists and stress stimuli. When activated, endothelial
cells release inflammatory mediators like interleukin-1,
tumor necrosis factor-α, etc. and induce adhesion mole-
cules like JAM-A and ZO-1, resulting in endothelial dys-
function and increased vascular permeability, particularly
atherosclerosis and cardiovascular diseases [35]. PPAR- γ
agonists can reduce the activation and inflammation of
endothelial cells [36–39]. PPAR-γ agonist inhibits endothe-
lial inflammation by suppressing inflammatory gene expres-
sion and therefore improves endothelial dysfunction [21].
In our study, rosiglitazone act positively in terms of
smooth muscle cell migration, endothelial cell repair, and
vascular inflammation, but negatively affects blood vessel
leakage, leading to leakage and increased edema. It
appears to be dependent on the PI3K/Akt pathway.
Endothelial cell migration is one of the main contributors
to the progression of atherosclerotic lesion formation. In
our data, rosiglitazone increased endothelial cell migration
compared with control in HUVECs. The effects of PPAR-
γ agonists on endothelial cell migration are debatable.
Goetze et al. [40] reported that PPAR-γ activators includ-
ing troglitazone and ciglitazone inhibit VEGF-induced
Fig. 6 Rosiglitazone suppressed the expression of tight junction proteins. a HUVECs were treated with rosiglitazone (10 μM) with or without PI3K
inhibitors LY294002 (1 μM), Akt inhibitor (3.5 μM), or PKCβ inhibitor (1.5 μM) simultaneously. Cells were stained with JAM-A antibody. b Cells were
stained with ZO-1 antibody. c and d Immunoblot analysis for the expression of JAM-A and ZO-1 (n = 4)
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endothelial cell migration in HUVECs. Others reported
that PPAR-γ activation inhibits VEGF-induced angiogen-
esis and EC proliferation and migration [41, 42]. By con-
trast, some authors suggested that PPAR-γ agonists
increased cell migration, like our results. Ciglitazone ele-
vated the expression of VEGF mRNA and protein and in-
creased cell viability and migration in breast cancer cells
[43]. In human, another PPAR-γ, pioglitazone increased
the number and endothelial progenitor cell migratory
function in patients with coronary artery disease [44].
VEGF promotes angiogenesis, increases macrophage
levels in peripheral blood, and enhances plaque progres-
sion, which leads to atherosclerosis and cardiovascular
disease [45].
In our experiments, rosiglitazone increased VEGF
expression in HUVECs. This observation is in agreement
with recent findings. Myofibroblasts have been shown to
up-regulate VEGF via oxidized low-density lipoprotein-
mediated PPAR-γ activation [46], and bovine articular
chondrocytes exhibit a PPAR-γ dependent biosynthesis
of VEGF [47]. Other PPAR-γ agonists, troglitazone and
ciglitazone, induced VEGF mRNA and protein expres-
sion from cultured keratinocytes [48]. However, the
effects of rosiglitazone or other PPAR-γ agonists on
VEGF expression differed under various conditions.
Rosiglitazone inhibited VEGF expression under the
high glucose condition [49], and rosiglitazone failed to
induce VEGF expression in keratinocytes [48]. In human
Ed – leukocytes, rosiglitazone inhibited VEGF secretion
by 63.7% [50]. The cause of these differences in VEGF
expression in response to rosiglitazone according to cell
types is still unresolved.
In our experiments, rosiglitazone increased endothelial
cell permeability and suppressed tight junction proteins as
well as migration, which occurred through the Akt
dependent pathway. Increased endothelial permeability was
observed in atherosclerosis. Low density lipoproteins (LDL)
can enter the vascular wall and become oxidized-LDL more
easily. At the same time vascular inflammation exacerbates
endothelial dysfunction [21]. Oxidized LDLs upregulate
VEGF expression in macrophages and endothelial cells
through activation of PPAR-γ [32]. VEGF has been
recognized as an angiogenic factor that induces vascular
permeability. Gavard J et al. reported that VEGF stimula-
tion promotes the beta-arrestin2-dependent endocytosis of
VE-cadherin, a key endothelial cell adhesion molecule,
Fig. 7 siRNA against Akt-1 inhibits rosiglitazone-induced cell migration. a HUVECs transfected with Akt-1 specific siRNA or nonspecific siRNA (control) were
treated with rosiglitazone (10 μM) and cell migration was assessed by a wound healing assay. Representative micrographs at × 400 magnifications (a) and
the distance moved of cells (b) (n = 4, * p < 0.01 compared with control, † p < 0.01 compared with control treated with rosiglitazone, p = NS, between
Akt siRNA treated groups). c and d Immunoblot analysis for the expression of phospho-Akt, phosphor-PKC β, VEGF, JAM-A, and ZO-1 (n = 4)
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disrupting the endothelial barrier function [51]. In
HUVECs, both decrease of tight junction protein and
increase of VEGF by rosiglitazone together contribute to
increased vascular permeability.
There are few data regarding the effects of rosiglitazone
on tight junctional proteins. In human nasal epithelial cells,
rosiglitazone enhanced the barrier function and upregula-
tion of tight junction molecules including claudin-1,
claudin-4, occludin, and tricellulin. In addition, PPAR-γ
agonist induced the activity of phospho-PKC. PPAR-γ
agonist upregulates the barrier function of tight junctions
of human nasal epithelial cells via a PKC signaling pathway
[52]. PPAR-γ agonists have protective effects against
HIV-induced disruption of brain endothelial cells. HIV re-
duced junctional protein such as JAM-A and ZO-1,
overexpression of PPAR-α or PPAR-γ attenuated HIV-
mediated dysregulation of tight junction proteins [53].
Conflicting data may result from tissue difference and fur-
ther investigation is required.
In endothelial cells, cellular signaling is dependent on
two major pathways – PI3K/Akt/mTOR pathway and
ERK/MAPK (extracellular signal-regulated kinases/mito-
gen-activated protein kinases) pathway. VEGF induced
endothelial cell proliferation and migration is dependent
on the Akt/endothelial synthase pathway [10, 54]. There
were conflicting data regarding the mechanism by which
rosiglitazone affects various cells including vascular
endothelial cells. In our data, rosiglitazone appears to
have a role through the PI3K/Akt/mTOR pathway.
Accordingly, compared to our study, Goetze et al., who
Fig. 8 Rosiglitazone increased neovascularization and vascular leakage in retina and aorta. Mice were given HFD with or without rosiglitazone (5 mg/kg/day)
and injected intraperitoneally with or without Akt inhibitor (0.15 mg/kg, 2 times in a week) for 8 weeks (n = 6/group). a Typical photographs from Evans
blue-albumin staining of retina whole-mount from mice. b Microscopic images of retinal flat-mounts and enlarged area. c Microscopic images after injection of
Akt inhibitor. d Microscopic image of aortic flat-mounts. e Microscopic images of the enlarged aortic area
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reported conflicting data regarding the effect of rosiglita-
zone on endothelial cell migration, reported the same
results showing that PPAR activators affect endothelial
cell migration by targeting Akt [40]. In addition, Wu et
al. reported that in HUVECs insulted with high glucose
rosiglitazone cellular apoptosis was inhibited through
the PI3K/Akt/eNOS pathway [55]. On the contrary, it
was suggested that rosiglitazone may influence apoptosis
of endothelial progenitor cells under the ERK/MAPK
pathway [56] and that rosiglitazone inhibits
inflammatory effects by a mechanism involving ERK in
human endothelial cells [57]. In ERK/MAPK pathway,
the ERK1 and ERK2 MPKs are activated by phosphoryl-
ation of threonine and tyrosine residues by the dual
specificity kinase MEK1, which induces their transloca-
tion into the nucleus where they activate or repress a
variety of transcription factors involved in growth and
differentiation [58]. The mechanisms by which PPARγ
receptor agonists regulate the ERK/MAPK pathway are
both direct and indirect mechanisms. The direct involve-
ment of the receptor in mediating TZD action is
strongly supported by the results of receptor silencing
experiments. However, because receptor silencing does
not completely revert TZD effect, a small component of
nonreceptorial mechanism cannot be ruled out [57].
It has been reported that PKCβ is activated and select-
ively inhibits the PI3K / Akt pathway when hyperglycemia
and free fatty acid increase in diabetic patients. In Qian Li
et al.’s study, they demonstrated that PKCβ overexpression
in ApoE−/− mice inhibits Akt activation by insulin, resulting
in atherosclerosis [59]. In another study, there is a report
that PKCβ has a negative correlation with endothelial
insulin signaling in diabetic patients [60].
Conclusion
There are still conflicts regarding the effect of PPAR-γ
agonist on endothelial cell dysfunction. However, PPAR-
γ agonist, rosiglitazone might induce endothelial cell
migration through the Akt pathway and cause instability
of endothelial barrier integrity and cytoskeletal structure,
resulting in increased vascular permeability, peripheral
edema, and congestive heart failure.
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